Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50–95 years: a cross-sectional study

The Lancet Neurology

Volumn 16, Issue 6, 2017, Pages 435-444

  Jack, Clifford R ^a   Wiste, Heather J ^a   Weigand, Stephen D ^a   Therneau, Terry M ^a   Knopman, David S ^a   Lowe, Val ^a   Vemuri, Prashanthi ^a   Mielke, Michelle M ^a   Roberts, Rosebud O ^a   Machulda, Mary M ^a   Senjem, Matthew L ^a   Gunter, Jeffrey L ^a   Rocca, Walter A ^a   Petersen, Ronald C ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; FLORTAUCIPIR; PITTSBURGH COMPOUND B;

ADJUSTMENT; ADULT; AGE; AGED; ALZHEIMER DISEASE; AMYLOIDOSIS; ARTICLE; BETA AMYLOIDOSIS; COGNITIVE DEFECT; CONTROLLED STUDY; CORTICAL THICKNESS (BRAIN); CROSS-SECTIONAL STUDY; DATA ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NERVE DEGENERATION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PERFORMANCE; POSITRON EMISSION TOMOGRAPHY; PRECURSOR; PREVALENCE; PRIORITY JOURNAL; SEX RATIO; TAUOPATHY; WHITE MATTER; CLASSIFICATION; DIAGNOSTIC IMAGING; METABOLISM; MINNESOTA; NEURODEGENERATIVE DISEASES; SEX DIFFERENCE; TAUOPATHIES; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; AMYLOID BETA-PEPTIDES; AMYLOIDOSIS; BIOMARKERS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MINNESOTA; NEURODEGENERATIVE DISEASES; POSITRON-EMISSION TOMOGRAPHY; PREVALENCE; SEX FACTORS; TAUOPATHIES;

EID: 85018161943     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(17)30077-7     Document Type: Article

References (41)

1. Sperling, RA, Aisen, PS, Beckett, LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Assocation workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7 (2011), 280–292.
2. McKhann, GM, Knopman, DS, Chertkow, H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Assocation Workgroup. Alzheimers Dement 7 (2011), 263–269.
3. Albert, MS, DeKosky, ST, Dickson, D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging and Alzheimer's Association Workgroup. Alzheimers Dement 7 (2011), 270–279.
4. Jack, CR Jr, Albert, MS, Knopman, DS, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7 (2011), 257–262.
5. Dubois, B, Feldman, HH, Jacova, C, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol 13 (2014), 614–629.
6. Dubois, B, Hampel, H, Feldman, HH, et al. Preclinical Alzheimer's disease: definition, natural history, and diagnostic criteria. Alzheimer's Dement 12 (2016), 292–323.
7. Jack, CR Jr, Knopman, DS, Weigand, SD, et al. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol 71 (2012), 765–775.
8. Knopman, DS, Jack, CR Jr, Wiste, HJ, et al. Brain injury biomarkers are not dependent on beta-amyloid in normal elderly. Ann Neurol 73 (2013), 472–480.
9. Mormino, EC, Betensky, RA, Hedden, T, et al. Synergistic effect of beta-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol 71 (2014), 1379–1385.
10. Vos, SJ, Xiong, C, Visser, PJ, et al. Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol 12 (2013), 957–965.
11. van Harten, AC, Smits, LL, Teunissen, CE, et al. Preclinical AD predicts decline in memory and executive functions in subjective complaints. Neurology 81 (2013), 1409–1416.
12. Caroli, A, Prestia, A, Galluzzi, S, et al. Mild cognitive impairment with suspected nonamyloid pathology (SNAP): prediction of progression. Neurology 84 (2015), 508–515.
13. Burnham, SC, Bourgeat, P, Dore, V, et al. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study. Lancet Neurol 15 (2016), 1044–1053.
14. Villemagne, VL, Fodero-Tavoletti, MT, Masters, CL, Rowe, CC, Tau imaging: early progress and future directions. Lancet Neurol 14 (2015), 114–124.
15. Johnson, KA, Shultz, A, Betensky, RA, et al. Tau positron emission tomographic imaging in aging and early Alzheimer's disease. Ann Neurol 79 (2016), 110–119.
16. Scholl, M, Lockhart, SN, Schonhaut, DR, et al. PET Imaging of tau deposition in the aging human brain. Neuron 89 (2016), 971–982.
17. Schwarz, AJ, Yu, P, Miller, BB, et al. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. Brain 139 (2016), 1539–1550.
18. Brier, MR, Gordon, B, Friedrichsen, K, et al. Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease. Science Trans Med, 8, 2016, 338ra66.
19. Blennow, K, Hampel, H, CSF markers for incipient Alzheimer's disease. Lancet Neurol 2 (2003), 605–613.
20. Jack, CR Jr, Bennett, DA, Blennow, K, et al. A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 87 (2016), 539–547.
21. Roberts, RO, Geda, YE, Knopman, DS, et al. The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiol 30 (2008), 58–69.
22. St Sauver, JL, Grossardt, BR, Leibson, CL, Yawn, BP, Melton, LJ, Rocca, WA, Generalizability of epidemiological findings and public health decisions: an illustration from the Rochester Epidemiology Project. Mayo Clinic Proc 87 (2012), 151–160.
23. Jack, CR, Wiste, HJ, Weigand, SD, et al. Defining imaging biomarker cut points for brain aging and Alzheimer's disease. Alzheimers Dement 13 (2017), 205–216.
24. Klunk, WE, Koeppe, RA, Price, JC, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement 11 (2015), 1–15.
25. Whitwell, JL, Tosakulwong, N, Weigand, SD, et al. Does amyloid deposition produce a specific atrophic signature in cognitively normal subjects?. Neuroimage Clin 2 (2013), 249–257.
26. Schwarz, CG, Gunter, JL, Wiste, HJ, et al. A large-scale comparison of cortical thickness and volume methods for measuring Alzheimer's disease severity. Neuroimage 11 (2016), 802–812.
27. Jack, CR Jr, Wiste, HJ, Weigand, SD, et al. Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings. Brain 138 (2015), 3747–3759.
28. Raz, L, Jayachandran, M, Tosakulwong, N, et al. Thrombogenic microvesicles and white matter hyperintensities in postmenopausal women. Neurology 80 (2013), 911–918.
29. Gouw, AA, Seewann, A, Vrenken, H, et al. Heterogeneity of white matter hyperintensities in Alzheimer's disease: post-mortem quantitative MRI and neuropathology. Brain 131 (2008), 3286–3298.
30. Vos, SJ, Gordon, BA, Su, Y, et al. NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers. Neurobiol Aging 44 (2016), 1–8.
31. Gordon, BA, Blazey, T, Su, Y, et al. Longitudinal beta-amyloid deposition and hippocampal volume in preclinical alzheimer disease and suspected non-Alzheimer disease pathophysiology. JAMA Neurol 73 (2016), 1192–1200.
32. Mormino, EC, Papp, KV, Rentz, DM, et al. Heterogeneity in suspected non-alzheimer disease pathophysiology among clinically normal older individuals. JAMA Neurol 73 (2016), 1185–1191.
33. Wisse, LE, Butala, N, Das, SR, et al. Suspected non-AD pathology in mild cognitive impairment. Neurobiol Aging 36 (2015), 3152–3162.
34. Nelson, PT, Head, E, Schmitt, FA, et al. Alzheimer's disease is not “brain aging”: neuropathological, genetic, and epidemiological human studies. Acta Neuropathologica 121 (2011), 571–587.
35. Crary, JF, Trojanowski, JQ, Schneider, JA, et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathologica 128 (2014), 755–766.
36. Jack, CR Jr, Knopman, DS, Jagust, WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 12 (2013), 207–216.
37. Barnes, J, Ridgway, GR, Bartlett, J, et al. Head size, age and gender adjustment in MRI studies: a necessary nuisance?. Neuroimage 53 (2010), 1244–1255.
38. Marquie, M, Normandin, MD, Vanderburg, CR, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol 78 (2015), 787–800.
39. Lowe, VJ, Curran, G, Fang, P, et al. An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathol Commun, 4, 2016, 58.
40. Jagust, W, Vulnerable neural systems and the borderland of brain aging and neurodegeneration. Neuron 77 (2013), 219–234.
41. Yeoman, M, Scutt, G, Faragher, R, Insights into CNS ageing from animal models of senescence. Nature Rev Neurosci 13 (2012), 435–445.